Champions Oncology, Inc. (CSBR) Announces Additions To Leadership Team To Support Continued Growth

HACKENSACK, N.J., Aug. 5, 2015 /PRNewswire/ -- Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that David DeOrnellis joined the organization as Global Director of Laboratory Operations; Mark Weinstein assumed the role of Chief Information Officer; and Jordan Rubinson was named Chief Commercial Officer.

David DeOrnellis joins Champions after 17 years of experience in biomedical research, laboratory management and leadership, holding such positions as Associate Director of LAS Technical Services at Novartis and Global Director of Quality Assurance at Harlan Laboratories. He will oversee all laboratory and implantation sites as the Company increases capacity to accommodate sustained growth and high quality.

Serving as the Company's CIO, Mark Weinstein will leverage his 25 years of experience as an IT professional in the healthcare, legal, and investment industries. Having served as Senior Technical Manager, Global Capital Markets for Bank of America, and Vice President of IT/CTO at Charles River Ventures, among other positions, Mark turned his focus to IT strategy and development for the biotechnology sector. His role at Champions includes developing and executing the Company's technology roadmap, and maximizing technology performance and impact.

Mr. Rubinson has been with Champions for more than four years and previously held the role of Executive Vice President and General Manager for Personalized Oncology Services. His new role includes responsibility for all of the Company's commercial strategy and development. Jordan has 17 years' experience in the pharmaceutical industry with Pfizer, GlaxoSmithKline, Aventis and most recently as the CEO of Polyheal Ltd., which is strategically allied with Teva Pharmaceuticals. Immediately prior, Mr. Rubinson worked at Pfizer as the marketing director in Israel, where he launched five new products in three years.

Joel Ackerman, the CEO of Champions Oncology commented, "These exciting changes to our management allow us to continue to capitalize on our current product and service offerings, and provide the foundation for the next stage of growth in our volumes and revenue. David, Mark and Jordan bring a long history of managerial and operational successes in their respective areas of expertise that will further solidify the position of Champions Oncology as a pioneer in the use patient-derived xenografts."

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's Champions TumorGraft® technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Champions TumorGraft models, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. Champions TumorGraft models are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit

To view the original version on PR Newswire, visit:

SOURCE Champions Oncology, Inc.